The rate of BCR-ABL1 decline after TKI commencement is a strong predictor of sustained treatment free remission. Shanmuganathan N, Branford S, Pagani IS, Ross, DM, Park S, Yong ASM, Braley J, Altamura H, Hiwase DK, Yeung DT, Kim D-W and Hughes TP.

Activity: Invited talks and oral presentationsOral conference presentations and other invited talks

Period2020
Event title22nd Annual John Goldman E-Conference on Chronic Myeloid Leukemia: Biology and Therapy, 2020.
Event typeConference
Degree of RecognitionInternational